HRT Financial LP filed a Form 4 with the SEC on November 19, 2026, disclosing a series of purchases and sales of bioAffinity Technologies, Inc. common stock and warrants between September 22 and October 1, 2026, that reduced its beneficial ownership to 10% or below.
Key Highlights
- Reporting person: HRT Financial LP, identified as a 10% owner of bioAffinity Technologies, Inc. (NASDAQ:BIAF).
- Earliest transaction date: September 22, 2026; transactions continued through October 1, 2026.
- Beneficial ownership at end of October 1, 2026: 116,658 shares of common stock, representing the level after the stake fell to 10% or below, according to the filing.
- Largest single-day purchase: 30,065 shares acquired on September 24, 2026, at a weighted average price of $7.668 per share.
- Largest single-day sale: 41,529 shares disposed of on October 1, 2026, at a weighted average price of $6.4466 per share.
- Warrant activity: Purchases and sales of warrants exercisable for common stock at an exercise price of $3,645 per whole share (as adjusted for reverse stock splits), with each warrant covering 1/450 of a share, were also reported across multiple dates.
- Ownership threshold: The filing notes that the October 1, 2026, transactions ended the reporting period because beneficial ownership fell to 10% or less of outstanding common stock.
HRT Financial LP's Multi-Day Trading Activity in bioAffinity Technologies Common Stock
According to the filing, HRT Financial LP conducted multiple purchases (transaction code P) and sales (transaction code S) of bioAffinity Technologies common stock on each trading day from September 22 through October 1, 2026. The reported prices are weighted averages, with the filing noting that each transaction was "executed in multiple trades" across a range of prices. HRT Financial LP has undertaken to provide full details of individual trade prices and share counts upon request to SEC staff, the issuer, or a security holder.
Beneficial ownership fluctuated across the reporting period. It stood at 126,519 shares after September 22, rose as high as 134,741 shares after September 29, and declined to 116,658 shares following the October 1 transactions. The filing states that the October 1 figure "represents the reporting person's beneficial ownership immediately after the transaction that reduced its beneficial ownership to 10% or less of the outstanding Common Stock, ending the period in which the transactions reported on this line occurred, including transactions not reported on this form."
In addition to common stock, HRT Financial LP reported warrant transactions on September 23, 24, 25, 28, and 29, 2026. Each warrant is described as exercisable for 1/450 of a share of common stock, with an exercise price of $3,645 per whole share as adjusted for the issuer's reverse stock splits. The warrant beneficial ownership figures cited in the filing reflect the end-of-day position after all transactions on each respective date, including transactions not separately reported on this form. The filing was signed by Adam Nunes on November 19, 2026.
What Was Disclosed
HRT Financial LP disclosed a series of common stock and warrant purchases and sales in bioAffinity Technologies between September 22 and October 1, 2026, with its reported beneficial ownership ending at 116,658 common shares after its stake fell to 10% or below.





Please wait processing your request...